Simtra BioPharma Solutions, a global contract development and manufacturing (CDMO) specialising in injectable medicines, has announced the purchase from Cook Group of a 65-acre property with more than 300,000 square feet of available space for expansion under-roof near its existing manufacturing facility in Bloomington, Indiana.

Leveraging Simtra's experience and expertise in manufacturing next generation oncology treatments, including ADCs, at its site in Halle/Westfalen, Germany, the addition of this site provides Simtra significant flexibility to rapidly expand its manufacturing footprint in the United States to respond to growing capacity demands from both new and existing customers.

“This purchase gives us the foundation to grow with purpose, building the advanced injectable capacity our customers need while strengthening our presence in North America,” said Franco Negron, Chief Executive Officer, Simtra BioPharma Solutions. “It reflects our long-term commitment to delivering vital injectable products and helping our customers navigate complex global supply chains.”

Simtra is evaluating a project to design and install manufacturing lines at the site, including the company's first US-based commercial-scale capacity for oncology-focused injectable drug products. The facility would run isolator-based vial and prefilled syringe filling lines. Simtra's model allows for ‘build-to-suit’ solutions that meet the unique needs of individual customers and their products.

This purchase complements other previously announced investments in the company's growth, including the USD 250 million construction project currently underway at Simtra's existing Bloomington manufacturing site, and the recently completed USD 100+ million new production building and USD 14 million conjugation and purification suite being built in Halle/Westfalen, Germany.